Ligand id: 2357

Name: ivabradine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ivabradine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 10
Topological polar surface area 60.47
Molecular weight 468.26
XLogP 2.57
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Across Europe, ivabradine has EMA approval for the symptomatic treatment of stable angina and chronic heart failure (HF) in patients with elevated heart rates. In August 2014 the US FDA granted priority review designation for ivabradine for the treatment of chronic HF, and in April 2015 granted approval for use of the drug in cases of worsening heart failure to reduce hospitalisation.
Mechanism Of Action and Pharmacodynamic Effects
Ivabradine inhibits the If current in the sinoatrial node (cardiac pacemaker) [2]. The heart rate is slowed down without any negative effects on myocardial contractility or ventricular repolarization.
External links